Overview
HGH-FRAG 176-191 is a specific, modified fragment of the Human Growth Hormone (HGH) molecule, consisting of the last 16 amino acids of the 191-amino acid sequence. It was developed to isolate the powerful fat-burning properties of growth hormone while stripping away its anabolic and diabetogenic effects. Unlike the complete HGH molecule, this fragment does not influence IGF-1 levels, bone growth, or insulin resistance, making it a targeted tool for lipid metabolism research.
Studies indicate that the peptide is particularly effective at stimulating lipolysis and preventing lipogenesis in adipose tissue. Beyond its primary role in weight management, emerging research suggests potential applications in blood sugar regulation and musculoskeletal repair, specifically regarding cartilage regeneration. It is frequently utilized in research settings as a safer alternative to HGH for addressing obesity and metabolic concerns.
Mechanism of action
This peptide isolates the C-terminal end of the Human Growth Hormone molecule to trigger fat metabolism via beta-3 adrenergic receptors without binding to GH receptors. By avoiding GH receptor binding, it avoids increasing IGF-1 levels or causing the insulin resistance often seen with full-length HGH.
Reported benefits
- ▸Accelerates fat mobilization and burning (lipolysis)
- ▸Inhibits the formation of new fatty acids (lipogenesis)
- ▸Supports cartilage regeneration and joint health
- ▸May help lower blood glucose levels without affecting insulin sensitivity
- ▸Promotes weight loss specifically in obese subjects without impacting lean mass
Reported side effects
- ·Redness or soreness at the injection site
- ·Potential hypoglycemia (low blood sugar)
Often stacked with
Hyaluronic acid (for cartilage)